



Correction to: Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee

Julia Paik¹ · Sean T. Duggan¹ · Susan J. Keam¹

Published online: 3 April 2019
© Springer Nature Switzerland AG 2019

Correction to: Drugs (2019) 79:455–462
<https://doi.org/10.1007/s40265-019-01083-3>

An Online First version of this article was made available online at <https://rd.springer.com/article/10.1007/s40265-019-01083-3> on the 8th of March 2019. Two errors were identified in the article; please note the following:

1. **Page 456, Column 2, Paragraph 1, Lines 2–7:** The following sentence, which previously read:

“Both triamcinolone acetonide ER 40 mg and triamcinolone acetonide CS 40 mg were associated with significant reductions in 24 h weighted mean serum cortisol (maximum reduction within 24 h of administration of 42.7 vs. 59.0%) and 24 h urinary cortisol excretion (43.8 vs. 58.5%) from baseline.”

Should read:

“Both triamcinolone acetonide ER 32 mg and triamcinolone acetonide CS 40 mg were associated with significant reductions in 24 h weighted mean serum cortisol (maximum reduction within 24 h of administration of 42.7 vs. 59.0%) and 24 h urinary cortisol excretion (43.8 vs. 58.5%) from baseline.”

2. **Page 457, Column 1, Paragraph 1, Lines 12–14:** The following sentence, which previously read:

“By contrast, the mean concentration of triamcinolone acetonide ER 6 weeks after treatment with 1 mL triamcinolone acetonide CS 40 mg was 0.0077 ng/mL [24].”

Should read:

“By contrast, the mean concentration of triamcinolone acetonide 6 weeks after treatment with 1 mL triamcinolone acetonide CS 40 mg was 0.0077 ng/mL [24].”

The original article can be found online at <https://doi.org/10.1007/s40265-019-01083-3>.

✉ Julia Paik
demail@springer.com

¹ Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand